Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia
Ohshima, A.; Yoshida, K.; Sato, T.; Miyazaki, S.; Yanagisawa, M.; Nakayama, Y.; Takahashi, T.; Mamiya, S.; Fukusima, Y.; Miura, A.B.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(1): 192-195
1987
ISSN/ISBN: 0385-0684 PMID: 3800405 Document Number: 286671
Seven patients with refractory and/or relapsed acute leukemia were treated with intermediate- or high-dose cytosine arabinoside (ara-C). One patient obtained complete remission and two achieved partial remission. We advocate intermediate ara-C in combination with anthracyclines for the treatment of patients with refractory and/or relapsed acute leukemia, because the toxicity is less severe than that of high-dose ara-C and the therapeutic results are not inferior to those obtained with high-dose ara-C. Kinetic differences in leukemic cells should be considered in order to obtain the maximum effect in intermediate- and high-dose ara-C therapy.